AstraZeneca (NYSE:AZN) and collaboration partner Merck (NYSE:MRK) announce additional positive results from a Phase 3 clinical trial, PROfound,
evaluating Lynparza (olaparib) in men with metastatic
castration-resistant prostate cancer (mCRPC) who have a homologous
recombination repair gene mutation (HRRm) and have progressed on prior
treatment with new hormonal agent (NHA) treatments (e.g. enzalutamide
and abiraterone).
Treatment with the PARP inhibitor resulted in a
statistically significant improvement in overall survival (OS) compared
to enzalutamide or abiraterone in subgroup of patients with BRCA1/2 or
ATM mutations.
The companies announced that PROfound met the primary endpoint in August 2019.
https://seekingalpha.com/news/3564080-astrazenecas-lynparza-extends-survival-in-certain-prostate-cancer-patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.